The Rheumatoid Arthritis Quality of Life Questionnaire

From WikiMD's Wellness Encyclopedia

The Rheumatoid Arthritis Quality of Life Questionnaire
[[File:|250px|alt=|]]
Pronunciation
Synonyms
Reference Range
Calculator
Purpose determine quality of life with Rheumatoid Arthritis
Test of
Based on
ICD-10-PCS
ICD-9-CM
MeSH
OPS-301 Code
Other Codes
MedlinePlus
eMedicine
LOINC
HCPCS-L2


The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease specific patient-reported outcome measure which determines the effect rheumatoid arthritis has on a patient’s quality of life.[1] The RAQoL has 30 items with a yes and no response format[2] and takes about six minutes to complete.[3]

Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.[4] The RAQoL is a self-assessment questionnaire, meaning patients fill out the survey themselves in order to avoid experimental error.[5]

History[edit | edit source]

The RAQoL was developed by Galen Research, the University of Leeds and the Academic Hospital Maastricht, and was first published in 1997.[6] It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis [7] and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.[8] Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.[9]

International Use[edit | edit source]

Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.[10] Validation studies have been performed in countries such as Sweden,[11] Argentina[12] and Australia[13] in order to confirm the responsiveness and validity of the language adaptations.

The RAQoL has been used in clinical studies in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of tocilizumab[14][15] and infliximab.[16][17]

References[edit | edit source]

  1. ↑ de Jong, Z., The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 878–883, DOI: 10.1093/rheumatology/36.8.878, Full text,
  2. ↑ Adams, Jo, Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology, Rheumatology, 2013, Vol. 52(Issue: 3), pp. 460–464, DOI: 10.1093/rheumatology/kes296, PMID: 23118412, Full text,
  3. ↑ de Jong, Z., The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 878–883, DOI: 10.1093/rheumatology/36.8.878, Full text,
  4. ↑ Tijhuis, G.J., The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire, Rheumatology, 2001, Vol. 40(Issue: 10), pp. 1112–1119, DOI: 10.1093/rheumatology/40.10.1112, Full text,
  5. ↑ Maska, L., Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)., Arthritis Care & Research, Vol. 63(Issue: Supplement S11), pp. S4–S13, DOI: 10.1002/acr.20620, PMID: 22588760,
  6. ↑ Whalley, D., Quality of life in rheumatoid arthritis., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 884–888, DOI: 10.1093/rheumatology/36.8.884, Full text,
  7. ↑ Marra, Carlo A., A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis., Social Science & Medicine, Vol. 60(Issue: 7), pp. 1571–1582, DOI: 10.1016/j.socscimed.2004.08.034, PMID: 15652688,
  8. ↑ Tijhuis, G.J., The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire, Rheumatology, 2001, Vol. 40(Issue: 10), pp. 1112–1119, DOI: 10.1093/rheumatology/40.10.1112, Full text,
  9. ↑ Lillegraven, Siri, Measuring disability and quality of life in established rheumatoid arthritis., Best Practice & Research Clinical Rheumatology., Vol. 21(Issue: 5), pp. 827–840, DOI: 10.1016/j.berh.2007.05.004, PMID: 17870030,
  10. ↑ Measures Database Full text, , Galen Research,
  11. ↑ Eberhardt, Kerstin, Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL., Scandinavian Journal of Rheumatology, Vol. 31(Issue: 1), pp. 6–12, DOI: 10.1080/030097402317255291, PMID: 11922201,
  12. ↑ Waimann, Christian A., Quality of life of patients with rheumatoid arthritis in Argentina: reliability, validity, and sensitivity to change of a Spanish version of the Rheumatoid Arthritis Quality of Life questionnaire., Clinical Rheumatology, Vol. 31(Issue: 7), pp. 1065–1071, DOI: 10.1007/s10067-013-2397-x, PMID: 24158632, Full text,
  13. ↑ Cox, S.R., Adaptation of the RAQoL for use in Australia, Rheumatology International, Vol. 27(Issue: 7), pp. 661–666, DOI: 10.1007/s00296-006-0287-0, PMID: 17195065,
  14. ↑ Dougados, Maxime, Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), Annals of the Rheumatic Diseases, 2013, Vol. 72(Issue: 1), pp. 43–50, DOI: 10.1136/annrheumdis-2011-201282, PMID: 22562983, PMC: 3551223,
  15. ↑ , Efficacy of tocilizumab in patients with rheumatoid arthritis, Current Controlled Trials, DOI: 10.1186/ISRCTN21216199, Full text,
  16. ↑ Quinn, Mark A., Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, Vol. 52(Issue: 1), pp. 27–35, DOI: 10.1002/art.20712, PMID: 15641102,
  17. ↑ Bejarano, Victoria, Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis., Rheumatology, 2010, Vol. 49(Issue: 10), pp. 1971–1974, DOI: 10.1093/rheumatology/keq194, PMID: 20595536, Full text,
Medicine-stub.png
This article is a stub related to medicine. You can help WikiMD by expanding it!
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.com/w/index.php?title=The_Rheumatoid_Arthritis_Quality_of_Life_Questionnaire&oldid=5248478"

Contributors: Prab R. Tumpati, MD